Document Detail


Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
MedLine Citation:
PMID:  15871849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: There are only little data about the effects of lipid-lowering drugs (LLDs) on the metabolism of essential n-6 and n-3 fatty acids in patients with established coronary heart disease (CHD). METHODS AND RESULTS: Male patients with CHD and high cholesterol levels (>6.2 mmol/L) were randomized (double-blind protocol) to receive either simvastatin 20mg (S) or fenofibrate 200mg daily (F) for 3 months. Dietary habits and plasma fatty acids were not different in the two groups at baseline. After treatment, there were significant changes in both the groups for the main n-6 fatty acids, with an increase in arachidonate (from 6.5+/-1.7% of total fatty acids to 7.5+/-2.1, p<0.001 in S and from 6.2+/-1.4 to 6.8+/-1.4, p<0.005 in F) and a decrease in linoleate (from 26.9+/-3.9 to 24.2+/-3.6, p<0.001, and from 27.8+/-3.4 to 26.1+/-4.2, p<0.05, in S and F, respectively). In addition, there was a decrease in two major n-3 fatty acids (alpha-linolenate and docosahexanoate, both p<0.05), but only in F. CONCLUSIONS: For the first time in a double-blind randomized study in CHD patients, we report that LLDs significantly alter the metabolism of essential fatty acids that are critically important for the pathogenesis and prevention of CHD. Further studies are urgently needed to examine the effects of higher dosages of statins (as currently proposed to reduce more cholesterol) on these essential fatty acids in the clinical setting and the crucial questions of whether specific dietary intervention (combining low intake of n-6 fatty acids and high intake of n-3 fatty acids) may improve the effectiveness of these drugs.
Authors:
Michel de Lorgeril; Patricia Salen; Annabelle Guiraud; Sabrina Zeghichi; François Boucher; Joël de Leiris
Related Documents :
16581239 - Fatty acid compositions of red blood cell phospholipids in children with autism.
9790399 - Fatty acid desaturase activities and polyunsaturated fatty acid composition in human li...
19776639 - Fads gene cluster polymorphisms: important modulators of fatty acid levels and their im...
17625029 - N-3 fatty acids, hypertension and risk of cognitive decline among older adults in the a...
15121409 - Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular ...
2550969 - Plasma fatty acid levels in patients with acquired immune deficiency syndrome and in co...
2981259 - Inhibition of cytotoxic t lymphocyte-mediated lysis by etya: effect independent of arac...
24798349 - Synthesis and structural characterization of al-containing interlayer-expanded-mww zeol...
3722299 - Analysis of amino acids as their tert.-butyldimethylsilyl derivatives by gas-liquid chr...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Nutrition, metabolism, and cardiovascular diseases : NMCD     Volume:  15     ISSN:  0939-4753     ISO Abbreviation:  Nutr Metab Cardiovasc Dis     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-05-05     Completed Date:  2005-11-04     Revised Date:  2006-02-09    
Medline Journal Info:
Nlm Unique ID:  9111474     Medline TA:  Nutr Metab Cardiovasc Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  36-41     Citation Subset:  IM    
Affiliation:
Laboratoire Nutrition, Vieillissement et Maladies Cardiovasculaires (NVMCV), UFR de Médecine, Université Joseph Fourier, Grenoble, France. michel.delorgeril@ujf-grenoble.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Antilipemic Agents / pharmacology*,  therapeutic use
Coronary Disease / blood,  drug therapy,  prevention & control*
Diet, Mediterranean
Double-Blind Method
Drug Synergism
Fatty Acids, Omega-3 / administration & dosage,  blood,  metabolism*
Fatty Acids, Omega-6 / administration & dosage,  blood,  metabolism*
Humans
Male
Middle Aged
Procetofen / pharmacology,  therapeutic use
Simvastatin / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Fatty Acids, Omega-3; 0/Fatty Acids, Omega-6; 49562-28-9/Procetofen; 79902-63-9/Simvastatin
Comments/Corrections
Comment In:
Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):3-5   [PMID:  15871844 ]
Atherosclerosis. 2005 Dec;183(2):367-8   [PMID:  16165140 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Investigation into the role of the hormone sensitive lipase -60C>G promoter variant in morbid obesit...
Next Document:  Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.